Graham Capital Management, L.P. Alnylam Pharmaceuticals, Inc. Transaction History
Graham Capital Management, L.P.
- $5.08 Billion
- Q4 2024
A detailed history of Graham Capital Management, L.P. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 2,350 shares of ALNY stock, worth $660,256. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,350
Previous 3,610
34.9%
Holding current value
$660,256
Previous $993,000
44.41%
% of portfolio
0.01%
Previous 0.02%
Shares
8 transactions
Others Institutions Holding ALNY
# of Institutions
671Shares Held
108MCall Options Held
839KPut Options Held
771K-
Capital World Investors Los Angeles, CA16.6MShares$4.66 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.58 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.68 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.96 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.23 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $34.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...